TX-FLUENCE
Fluence , a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its full speaker schedule, including CEO David Cohen and General Manager of EMEA Timo Bongartz, at the 2022 GreenTech Amsterdam conference, the leading global meeting place for the horticulture industry.
Fluence speakers will discuss new innovations in data-driven horticulture strategies, the latest research on the effects of next-generation lighting solutions for plant growth and the role of LED lighting in the cannabis industry. Fluence horticulture specialists will also be available to discuss the company’s comprehensive product suite at booth No. 05.524. This includes display of Fluence’s newest luminaires and lighting controls: RAPTR —the company’s one-to-one HPS replacement fixture—Wireless Flex Dimming , SPYDR Fang , VYNE and RAZR Modular System .
“GreenTech Amsterdam is one of the world’s premier agricultural conferences. The team at Fluence is excited to stand alongside some of the most notable experts in the industry in a series of informative panels for growers,” Cohen said. “I always value the opportunity to speak face-to-face with our customers and gain valuable insight into what solutions growers are looking for. We’re confident that Fluence’s expanded product suite will support and exceed grower’s expectations for crop performance.”
Fluence’s speaking sessions will include:
- Medicinal cannabis in the spotlight (June 14, 11:00-11:45 a.m. CET) , featuring Casey Rivero, cannabis solutions architect for Fluence
- Data-driven horticulture: Collecting and interpreting data, how much is enough? (June 14, 3:30-4:15 p.m. CET) , moderated by Theo Tekstra, technical director of EMEA for Fluence
- Leading the Cannabis Industry into the Next Decade (June 15, 2:15-3:00 p.m. CET) , moderated by Fluence CEO David Cohen and featuring Elad Toby, founder of Remy, Levin Amweg, co-founder and CEO of Cannerald, and Timo Bongartz, Fluence’s general manager of EMEA
- Save energy by applying new innovations and solutions (June 16, 11:45 a.m. - 12:30 p.m. CET) , featuring Theo Tekstra, technical director of EMEA for Fluence
- Is Indoor Growing Sustainable? (June 16, 1:15-2:00 p.m. CET) , featuring Timo Bongartz, general manager of EMEA for Fluence
“Our priority is to create and deploy the most advanced lighting solutions for the entire EMEA region and beyond,” Bongartz said. “GreenTech is a critical opportunity to illuminate growers on what’s possible when they convert to Fluence’s LED lighting solutions. Growers, partners and colleagues: We can’t wait to see you!”
For more information on Fluence, its products and the future of LED lighting, visit the team at booth No. 05.524, or visit www.fluence.science .
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220610005011/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom